CALIXAR team will attend at the EU-Japan Biotech and Pharma virtual partnering conference, from September 26 to 30, 2022 in order to discuss about the commercial and scientific opportunities related to our activities.
CALIXAR is a biotech company focused on the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …). The company is currently working on the pipeline extension of highly druggable membrane protein targets and native antigens. In the next few years, CALIXAR will therefore be able to provide to Pharma / Biotech companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR aims at becoming a leader in the complex therapeutic targets-based (membrane proteins) drug development at the early discovery stage. Indeed, it is a thriving market expected to be worth 70 billion euros by 2025.
About Bio Japan:
The EU-Japan Biotech & Pharma Partnering Conference 2022 offers business contacts to industry professionals who are looking for potential partners in the Biotech and Pharma sector.
The event is co-organized by the Osaka Prefectural Government, the EU-Japan Centre for Industrial Cooperation and the Enterprise Europe Network. It will be supported by various Bioclusters from Japan and Europe.
For more information and meet us: Bio Japan